A prodrug compound of an orally administered dual- or tri-agonistic polypeptide molecule and its uses

By developing prodrug compounds of oral dual- or tri-agonistic peptide molecules, the problem of short dosing cycles in existing technologies has been solved, enabling a once-weekly oral treatment regimen suitable for the treatment of a variety of diseases.

CN123106875APending Publication Date: 2026-11-17BRIGHTGENE BIO MEDICAL TECHNOLOGY CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202510619290.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Currently, there is a lack of prodrug technology for dual- or tri-agonistic peptide molecules such as GLP-1, GIP, and GCG, which makes it impossible to achieve oral treatment regimens with extended dosing cycles.

Method used

A prodrug compound for oral administration of a bi- or tri-agonistic polypeptide molecule has been developed, comprising a specific structure FZ, wherein F is the specific structure and Z is the polypeptide or analogue thereof, linked by an amide bond, having a lipophilic moiety of the distal carboxylic acid, suitable for oral administration.

Benefits of technology

It enables once-weekly oral administration, improving patient convenience and compliance, and is suitable for the treatment of diabetes, obesity, non-alcoholic fatty liver disease, cardiovascular disease, neurodegenerative diseases, chronic kidney disease, diabetic nephropathy, and heart failure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_5
    Figure SMS_5
  • Figure SMS_6
    Figure SMS_6
Patent Text Reader

Abstract

This invention relates to the field of biomedical technology, specifically to an oral prodrug compound of a biagonal or triagonal agonist polypeptide molecule and its uses. The oral biagonal or triagonal agonist polypeptide molecule of this invention is suitable for oral administration, with a dosing frequency of more than once a week. A treatment regimen of once-weekly oral administration instead of once-daily oral administration can improve patient convenience and compliance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, specifically to a prodrug compound of an orally administered bi- or tri-agonistic polypeptide molecule and its uses. Background Technology

[0002] GLP-1 is a 31-amino acid polypeptide expressed by the proglucagon gene in L cells of the intestinal mucosa. It mainly acts on the GLP-1 receptor (GLP-1R), stimulating insulin secretion, inhibiting glucagon secretion, protecting pancreatic β-cells, and playing a physiological role in regulating blood glucose homeostasis. At the same time, it can inhibit food intake and gastric emptying through central nervous system signaling pathways, increase satiety, and thus reduce weight.

[0003] GIP is a 42-amino acid single-chain polypeptide produced by small intestinal mucosal K cells. It mainly acts on GIP receptors (GIPR) in pancreatic islet cells and adipocytes. GIP promotes insulin secretion in a glucose-dependent manner, enhances the mass of pancreatic β-cells, stimulates insulin secretion, inhibits gastric acid secretion, and slows down gastric motility.

[0004] GCG is a 29-amino acid polypeptide expressed and secreted by the proglucagon gene in pancreatic α-cells. It acts on glucagon receptors (GCGR), primarily located in the liver and kidneys, stimulating glycogenolysis, raising blood glucose levels, activating lipases, promoting fat breakdown, and simultaneously enhancing fatty acid oxidation, leading to increased ketone body production. Studies have shown that GCG has a certain effect on reducing food intake, increasing energy expenditure from adipose tissue, and reducing body fat.

[0005] Based on the physiological functions of GLP-1, GIP, and GCG, multiple studies have found that stimulating the integration of the effects of two or three of these drugs at multiple targets can achieve better diabetes and obesity control than monotherapy.

[0006] A prodrug is a compound that undergoes a chemical transformation in the body through enzymatic or non-enzymatic processes, resulting in the release of a parent drug. The parent drug is the pharmacologically active compound released from the prodrug during its transformation. The intact prodrug does not exert the intended pharmacological activity to a significant extent; for example, it does not exert the intended pharmacological activity to the degree that would make it incompatible with the intended treatment regimen. Once the parent drug is released, the pharmacological activity associated with the intended treatment of the prodrug is derived from the parent drug.

[0007] Prodrug technology can be used to generate compounds with properties that have a specific dosing frequency.

[0008] Currently, there is a lack of research on prodrug technology for dual- or tri-agonistic peptide molecules such as GLP-1, GIP, and GCG. If oral prodrugs of dual- or tri-agonistic peptide molecules that can prolong the dosing cycle can be developed, they will have very good application prospects. Summary of the Invention

[0009] The purpose of this invention is to provide a prodrug of an orally administered bi- or tri-agonistic polypeptide molecule suitable for oral administration.

[0010] Prodrug compounds containing Formula I:

[0011] FZ (Formula I)

[0012] F represents Equation II:

[0013]

[0014] Where X represents Equation III:

[0015] Where p = 1-5 (Equation III);

[0016] Wherein Y comprises a lipophilic moiety having a distal carboxylic acid; or a pharmaceutically acceptable salt, ester, or amide thereof;

[0017] Wherein Z is a polypeptide or its analogue, preferably, the polypeptide is a dual receptor agonist of GLP-1 and GIP, a dual receptor agonist of GLP-1 and Gcg, or a triple receptor agonist of GLP-1, GIP and Gcg.

[0018] The lipophilic portion having a distal carboxylic acid is selected from the portions of chemical formulas 12 and 13:

[0019] Chemical formula 12:

[0020] Where n = 12, 14, 16 or 18;

[0021] Chemical formula 13:

[0022] Where m = 9 or 10.

[0023] Y contains portions selected from chemical formulas 6 and 7:

[0024] Chemical formula 6:

[0025]

[0026] Chemical Formula 7:

[0027]

[0028] The above prodrug compound, Y, is of formula IV:

[0029] A5-A4-A3-A2-A1-(Formula IV)

[0030] A1, A2, and A3 are each individually selected from chemical formulas 6, 7, 8, 9, 10, and 11, or they do not exist.

[0031] Chemical formula 8:

[0032]

[0033] Chemical formula 9:

[0034]

[0035] Chemical Formula 10:

[0036]

[0037] Chemical Formula 11:

[0038]

[0039] A4 is selected from chemical formulas 6 and 7;

[0040] A5 is selected from chemical formulas 12 and 13.

[0041] In the aforementioned prodrug compound, residues A5, A4, A3, A2, and A1 are interconnected via amide bonds.

[0042] The prodrug compound Z is selected from the following polypeptides or their derivatives:

[0043]

[0044]

[0045]

[0046]

[0047]

[0048] In the prodrug compound of this invention, F is selected from the following structures:

[0049] Gly-N α -2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]ethyl-Gly-;

[0050] Gly-N α-2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]butyl-Gly-;

[0051] Gly-N α -2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]ethyl-Gly-;

[0052] Gly-N α -2-[[(4S)-4-carboxy-4-(13-carboxytadecaylamino)butyryl]amino]ethyl-Gly-;

[0053] Gly-N α -2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyryl)amino]ethyl-Gly-;

[0054] Gly-N α -2-[[2-[2-[2-[2-[2-[2-[(4S)-4-carboxy-4-[15-carboxypentadecanoacylamino)-butyryl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethyl-Gly-;

[0055] Gly-N α -2-[[(4S)-4-carboxy-4-[[4S]-4-carboxy-4-[[(4S)-4-carboxy-4-(15-carboxypentadecanoamino)butyryl]amino]butyryl]amino]butyryl]amino]ethyl-Gly-;

[0056] Gly-N α -4-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]butyl-Gly-;

[0057] Gly-N α -2-[[(2S)-4-carboxy-2-[[2S]-4-carboxy-2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]butyryl]amino]butyryl]amino]ethyl-Gly-;

[0058] Gly-N α -2-[[(2S)-2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]-3-hydroxypropionyl]amino]ethyl-Gly-;

[0059] Gly-N α-2-[[2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]-acetyl]amino]ethyl-Gly-;

[0060] Gly-N α -2-[[(4S)-4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butyryl]amino]-ethyl-Gly-;Gly-N α -2-[[(4S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)butyryl]amino]ethyl-Gly-;

[0061] Gly-N α -2-[[(4S)-4-carboxy-4-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]butyryl]amino]ethyl-Gly-;

[0062] Gly-N α -2-[[(2S)-2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]-3-hydroxypropionyl]amino]ethyl-Gly-;

[0063] Gly-N α -2-[[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]acetyl]amino]ethyl-Gly-;

[0064] Gly-N α -2-[[(4S)-4-carboxy-2-(17-carboxyheptadecylamino)butyryl]amino]ethyl]-Gly-;

[0065] Gly-N α -3-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]propyl]-Gly-;

[0066] Gly-N α -5-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]pentyl]-Gly-;

[0067] Gly-N α -6-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butyryl]amino]hexyl]-Gly-.

[0068] The oral prodrugs of the bi- or tri-agonistic polypeptide molecules of the present invention are used to treat diabetes, obesity, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, cardiovascular disease, neurodegenerative diseases, chronic kidney disease, diabetic nephropathy, peripheral artery disease and / or (ix) heart failure.

[0069] The present invention relates to an oral prodrug of a dual- or tri-agonistic polypeptide molecule suitable for oral administration, with a dosing frequency of more than one week. The treatment regimen of once-weekly oral administration instead of once-daily oral administration improves patient convenience and compliance. Detailed Implementation

[0070] For those skilled in the art, various other corresponding changes and modifications can be made based on the technical solutions and concepts described above, and all such changes and modifications should fall within the protection scope of the claims of this invention.

[0071] This invention comprises a prodrug compound of formula I:

[0072] FZ (Formula I)

[0073] F represents Equation II:

[0074]

[0075] Where X represents Equation III:

[0076] Where p = 1-5 (Equation III);

[0077] Wherein Y comprises a lipophilic moiety having a distal carboxylic acid; or a pharmaceutically acceptable salt, ester, or amide thereof;

[0078] Wherein Z is a polypeptide or its analogue, preferably, the polypeptide is a dual receptor agonist of GLP-1 and GIP, a dual receptor agonist of GLP-1 and Gcg, or a triple receptor agonist of GLP-1, GIP and Gcg.

[0079] The lipophilic portion having a distal carboxylic acid is selected from the portions of chemical formulas 12 and 13:

[0080] Chemical formula 12:

[0081] Where n = 12, 14, 16 or 18;

[0082] Chemical formula 13:

[0083] Where m = 9 or 10.

[0084] Y contains portions selected from chemical formulas 6 and 7:

[0085] Chemical formula 6:

[0086]

[0087] Chemical Formula 7:

[0088]

[0089] The above prodrug compound, Y, is of formula IV:

[0090] A5-A4-A3-A2-A1-(Formula IV)

[0091] A1, A2, and A3 are each individually selected from chemical formulas 6, 7, 8, 9, 10, and 11, or they do not exist.

[0092] Chemical formula 8:

[0093]

[0094] Chemical formula 9:

[0095]

[0096] Chemical Formula 10:

[0097]

[0098] Chemical Formula 11:

[0099]

[0100] A4 is selected from chemical formulas 6 and 7;

[0101] A5 is selected from chemical formulas 12 and 13.

[0102] In the aforementioned prodrug compound, residues A5, A4, A3, A2, and A1 are interconnected via amide bonds.

[0103] The prodrug compound Z is selected from the following polypeptides or their derivatives:

[0104]

[0105]

[0106]

[0107]

[0108] In the prodrug compound of this invention, F is selected from the following structures:

[0109] Gly-N α -2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]ethyl-Gly-;

[0110] Gly-N α -2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]butyl-Gly-;

[0111] Gly-N α -2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]ethyl-Gly-;

[0112] Gly-N α -2-[[(4S)-4-carboxy-4-(13-carboxytadecaylamino)butyryl]amino]ethyl-Gly-;

[0113] Gly-N α -2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyryl)amino]ethyl-Gly-;

[0114] Gly-N α -2-[[2-[2-[2-[2-[2-[2-[(4S)-4-carboxy-4-[15-carboxypentadecanoacylamino)-butyryl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethyl-Gly-;

[0115] Gly-N α -2-[[(4S)-4-carboxy-4-[[4S]-4-carboxy-4-[[(4S)-4-carboxy-4-(15-carboxypentadecanoamino)butyryl]amino]butyryl]amino]butyryl]amino]ethyl-Gly-;

[0116] Gly-N α -4-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]butyl-Gly-;

[0117] Gly-N α -2-[[(2S)-4-carboxy-2-[[2S]-4-carboxy-2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]butyryl]amino]butyryl]amino]ethyl-Gly-;

[0118] Gly-N α-2-[[(2S)-2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]-3-hydroxypropionyl]amino]ethyl-Gly-;

[0119] Gly-N α -2-[[2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]-acetyl]amino]ethyl-Gly-;

[0120] Gly-N α -2-[[(4S)-4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butyryl]amino]-ethyl-Gly-;

[0121] Gly-N α -2-[[(4S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)butyryl]amino]ethyl-Gly-;

[0122] Gly-N α -2-[[(4S)-4-carboxy-4-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]butyryl

[0123] [By]amino[By]ethyl-Gly-;

[0124] Gly-N α -2-[[(2S)-2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]-3-hydroxypropionyl

[0125] [By]amino[By]ethyl-Gly-;

[0126] Gly-N α -2-[[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]acetyl]amino]ethyl-Gly-;

[0127] Gly-N α -2-[[(4S)-4-carboxy-2-(17-carboxyheptadecylamino)butyryl]amino]ethyl]-Gly-;

[0128] Gly-N α -3-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]propyl]-Gly-;

[0129] Gly-N α-5-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]pentyl]-Gly-;

[0130] Gly-N α -6-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butyryl]amino]hexyl]-Gly-.

[0131] A pharmaceutical composition comprising the above-described prodrug compound and pharmaceutically acceptable excipients.

[0132] The above-mentioned prodrug compound or pharmaceutical composition, and its use in the preparation of a medicine for treating diabetes, obesity, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, cardiovascular disease, neurodegenerative diseases, chronic kidney disease, diabetic nephropathy, peripheral artery disease, and / or heart failure.

[0133] The prodrug compound of the present invention can be prepared according to the method disclosed in patent CN116490212A, the only difference being that the polypeptide compound Z of the present invention is used instead of smegglutinin in CN116490212A.

[0134] The present invention provides a prodrug with a conversion half-life suitable for once-weekly dosing, an observed terminal half-life suitable for once-weekly dosing, and high oral bioavailability.

[0135] The polypeptide compounds involved in the prodrug compounds of this invention can be prepared according to existing publicly available synthetic methods, for example, by referring to the following patents: WO2021 / 093883A1, WO2021 / 239082A1, WO2021 / 143810A1, WO2022 / 247950A1, CN107735100B.

[0136] The preparation of the F structure involved in the prodrug compound of this invention can be carried out according to method A disclosed in patent CN116490212A.

Claims

1. Prodrug compounds containing Formula I: FZ (Formula I) F represents Equation II: Where X represents Equation III: Where p = 1-5 (Equation III); Wherein Y comprises a lipophilic moiety having a distal carboxylic acid; or a pharmaceutically acceptable salt, ester, or amide thereof; Wherein Z is a polypeptide or its analogue, preferably, the polypeptide is a dual receptor agonist of GLP-1 and GIP, a dual receptor agonist of GLP-1 and Gcg, or a triple receptor agonist of GLP-1, GIP and Gcg.

2. The prodrug compound according to claim 1, characterized in that, The N-terminal amino group of the polypeptide is linked to F via an amide bond.

3. The prodrug compound according to claim 1, characterized in that, The lipophilic portion having a distal carboxylic acid is selected from the portions of chemical formulas 12 and 13: Chemical formula 12: Where n = 12, 14, 16 or 18; Chemical formula 13: Where m = 9 or 10.

4. The prodrug compound according to any one of claims 1-3, characterized in that, Y contains portions selected from chemical formulas 6 and 7: Chemical formula 6: Chemical Formula 7:

5. The prodrug compound according to any one of claims 1-3, characterized in that, Y represents equation IV: A5-A4-A3-A2-A1-(Formula IV) A1, A2, and A3 are each individually selected from chemical formulas 6, 7, 8, 9, 10, and 11, or they do not exist. Chemical formula 8: Chemical formula 9: Chemical Formula 10: Chemical Formula 11: A4 is selected from chemical formulas 6 and 7; A5 is selected from chemical formulas 12 and 13.

6. The prodrug compound according to claim 5, wherein residues A5, A4, A3, A2, and A1 are interconnected by amide bonds.

7. The prodrug compound according to any one of claims 1-6, wherein Z is selected from the following polypeptides or derivatives thereof:

8. The prodrug compound according to any one of claims 1-7, wherein F is selected from the following structures: Gly-N α -2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butyryl]amino]ethyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]butyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]ethyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-4-(13-carboxytadecaylamino)butyryl]amino]ethyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyryl)amino]ethyl-Gly-; Gly-N α -2-[[2-[2-[2-[2-[2-[2-[(4S)-4-carboxy-4-[15-carboxypentadecanoacylamino)-butyryl]amino]ethoxy]ethoxy]acetyl]amino]ethoxy]ethoxy]acetyl]amino]ethyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-4-[[4S]-4-carboxy-4-[[(4S)-4-carboxy-4-(15-carboxypentadecanoamino)butyryl]amino]butyryl]amino]butyryl]amino]ethyl-Gly-; Gly-N α -4-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]butyl-Gly-; Gly-N α -2-[[(2S)-4-carboxy-2-[[2S]-4-carboxy-2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]butyryl]amino]butyryl]amino]ethyl-Gly-; Gly-N α -2-[[(2S)-2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]-3-hydroxypropionyl]amino]ethyl-Gly-; Gly-N α -2-[[2-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]-acetyl]amino]ethyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-4-[11-(4-carboxyphenoxy)undecanoylamino]butyryl]amino]-ethyl-Gly-;Gly-N α -2-[[(4S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)butyryl]amino]ethyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-4-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]butyryl]amino]ethyl-Gly-; Gly-N α -2-[[(2S)-2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]-3-hydroxypropionyl]amino]ethyl-Gly-; Gly-N α -2-[[2-[[(4S)-4-carboxy-4-(17-carboxyheptadecylamino)butyryl]amino]acetyl]amino]ethyl-Gly-; Gly-N α -2-[[(4S)-4-carboxy-2-(17-carboxyheptadecylamino)butyryl]amino]ethyl]-Gly-; Gly-N α -3-[[(4S)-4-carboxy-4-(15-carboxypentadecanoacylamino)butyryl]amino]propyl]-Gly-; Gly-N α -5-[[(4S)-4-carboxy-4-(15-carboxypentadecanoamino)butyryl]amino]pentyl]-Gly-; Gly-N α -6-[[(4S)-4-carboxy-4-(15-carboxypentadecanoylamino)butyryl]amino]hexyl]-Gly-.

9. A pharmaceutical composition comprising a prodrug compound as described in any one of claims 1-8, and a pharmaceutically acceptable excipient.

10. The prodrug compound according to any one of claims 1-8 or the pharmaceutical composition according to claim 9, in the preparation of a medicament for treating diabetes, obesity, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, cardiovascular disease, neurodegenerative diseases, chronic kidney disease, diabetic nephropathy, peripheral artery disease, and / or heart failure.

Citation Information

Patent Citations

  • Glucagon and GLP-1 co-agonist compounds

    CN107735100B

  • GLP-1 prodrugs and uses thereof

    CN116490212A

  • Dual receptor-acting agonist compounds and pharmaceutical composition thereof

    WO2021093883A1

  • Polypeptide compound and use thereof

    WO2021143810A1

  • Dual-agonist compound for both GLP-1 and GIP receptors and application thereof

    WO2021239082A1